A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Thrombosis and Haemostasis
Stephan GlundPaul Reilly

Abstract

Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran. In this first-in-human, single-rising-dose study, we investigated the pharmacokinetics, safety and tolerability of idarucizumab. Healthy male volunteers aged 18-45 years received between 20 mg and 8 g idarucizumab as a 1-hour intravenous infusion in 10 sequential dose groups, or 1, 2 or 4 g idarucizumab as a 5-minute infusion. Subjects within each dose group were randomised 3:1 to idarucizumab or placebo. A total of 110 randomised subjects received study drug (27 placebo, 83 idarucizumab). Peak and total exposure to idarucizumab increased proportionally with dose. Maximum plasma concentrations were achieved near the end of infusion, followed by a rapid decline, with an initial idarucizumab half-life of ~45 minutes. For the 5-minute infusions, this resulted in a reduction of plasma concentrations to less than 5 % of peak within 4 hours. Idarucizumab (in the absence of dabigatran) had no effect on coagulation parameters or endogenous thrombin potential. Overall adverse event (AE) frequency was similar for idarucizumab and placebo, and no relationship with idarucizumab dose was observed. D...Continue Reading

References

Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Dec 8, 2009·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-COVER Study Group
May 4, 2010·Thrombosis Research·R J FriedmanUNKNOWN RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees
Nov 5, 2010·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators
Jan 10, 2012·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Joachim Stangier, Martin Feuring
Jan 18, 2012·Journal of Clinical Pharmacology·Bernd Meibohm, Honghui Zhou
Mar 31, 2012·American Journal of Hematology·Kenneth A Bauer
Aug 10, 2012·Physiology·Erik I ChristensenRikke Nielsen
Mar 12, 2013·Blood·Felix SchieleTobias Litzenburger
Dec 18, 2013·Circulation·Sam SchulmanUNKNOWN RE-COVER II Trial Investigators

❮ Previous
Next ❯

Citations

Jun 17, 2015·Expert Opinion on Pharmacotherapy·Marco Proietti, Gregory Y H Lip
Nov 13, 2015·Expert Opinion on Pharmacotherapy·Mikhail S Dzeshka, Gregory Y H Lip
Dec 3, 2015·Journal of Thrombosis and Thrombolysis·Konstantinos N Aronis, Elaine M Hylek
Aug 21, 2016·Indian Heart Journal·Jamshed DalalPrashant Rana
Jan 19, 2016·Medicina clínica·Antonio Gómez-Outes, Ramón Lecumberri
Nov 1, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Steen HustedWillemijn J Comuth
Jan 18, 2016·Journal of Cardiothoracic and Vascular Anesthesia·Giulia Beatrice CrapelliMarco Ranucci
Nov 19, 2015·Drugs·Celeste B Burness
May 1, 2015·Thrombosis and Haemostasis·Eva-Luise Hobl, Bernd Jilma
May 29, 2015·Thrombosis and Haemostasis·Charles V PollackJeffrey I Weitz
Apr 3, 2015·Thrombosis and Haemostasis·Andreas GreinacherKathleen Selleng
Jun 4, 2016·Air Medical Journal·Richard L Summers, Sarah A Sterling
Sep 18, 2015·Experimental Hematology & Oncology·Arundhati Das, Delong Liu
Apr 29, 2015·International Journal of Emergency Medicine·Terrance R McGovernNilesh Patel
Apr 16, 2016·Journal of Cardiothoracic and Vascular Anesthesia·Graham M LohrmannHarish Ramakrishna
Aug 5, 2015·Current Cardiology Reports·Yi Dong, Qiang Dong
Jun 25, 2015·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Christian SticherlingGregory Y H Lip
Jun 23, 2015·The New England Journal of Medicine·Charles V PollackJeffrey I Weitz
May 6, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Sebastian WerthJan Beyer-Westendorf
Apr 25, 2016·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·Ana-Catarina Pinho-GomesJonathan Ghosh
Jun 15, 2016·American Heart Journal·James A ReiffelUNKNOWN Cardiac Safety Research Consortium presenters and participants
May 26, 2016·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Marijke PeetermansPeter Verhamme
May 12, 2016·Expert Review of Hematology·Thomas VanasschePeter Verhamme
Jun 15, 2016·Journal des maladies vasculaires·A GodierS Susen
Jun 17, 2016·CPT: Pharmacometrics & Systems Pharmacology·J AlmquistP Gennemark
Jun 29, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Laurent BertolettiSilvy Laporte
Jul 1, 2016·Expert Review of Cardiovascular Therapy·Neel R Sodha, Frank W Sellke
Jul 9, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Yahiya Y Syed
Aug 30, 2016·The American Journal of Medicine·Menno V Huisman, John Fanikos
Sep 10, 2016·The Canadian Journal of Cardiology·Laurent MacleUNKNOWN CCS Atrial Fibrillation Guidelines Committee
Aug 29, 2016·The American Journal of Medicine·Charles V Pollack
Sep 18, 2016·Hematology/oncology Clinics of North America·Benjamin R BellJames D Douketis
Oct 5, 2016·The American Journal of Emergency Medicine·Charles V Pollack
Oct 5, 2016·The American Journal of Emergency Medicine·Menno V Huisman, John Fanikos
Dec 3, 2016·Thrombosis and Haemostasis·Michael SchmohlJoachim Stangier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.